High performance drug development team
Our industry-leading team combines polymer chemistry, microbiology and molecular biology expertise with advanced product development know-how. By targeting polysaccharide therapeutics to mucosal surface biology in pulmonary and GI diseases, we work to create breakthrough drugs for superior therapeutic impact.
William Wiesmann, MD
Chief Executive Officer, Chairman of the Board, and Co-founder
Dr. Wiesmann is an accomplished physician, medical scientist, and program manager with experience in cell biology, systems biology, medical device development and extensive experience leading and conducting basic scientific and medical research. He served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel technologies for improved battlefield survival until he retired from the Army as a colonel in 1997. His innovations, which include the LSTAT Transportable Life Support System, the Advanced Surgical Suite for Trauma Casualties (ASSTC), the SAVe ventilators, and the HemCon hemostatic bandages, have transformed medicine both on the battlefield and in civilian trauma centers. In 2004, the military named the 4-by-4-inch HemCon bandage one of the year’s “Top 10 Greatest Inventions” for its ability to stop seriously wounded soldiers from bleeding to death. He holds 59 awarded or pending patents from his work in biosensors, automated diagnostic devices, advanced tissue engineering, wound care, and infection control. Dr. Wiesmann has been published in more than 75 peer-reviewed medical journals.
Dr. Wiesmann has received many honors for his development work in government, including the US Army Meritorious Service Medal, the US Army R & D Achievement Award, and the Army Commendation Medal. He was awarded an honorary Doctor of Science degree from the University of Cincinnati.
He is a co-founder of Hawaii Chitopure, BioSTAR West, Tissue Genesis, AutoMedx Inc., and Synedgen, Inc.
Shenda Baker, PhD
President, Chief Operating Officer, Treasurer and Co-founder
Dr. Shenda Baker has more than 20 years of experience conducting, generating funds for, and directing chemistry, materials science, and biochemistry research. She provides scientific leadership, manages the intellectual property as well as the scientific and regulatory collaborations, and provides financial and organizational oversight at Synedgen. Previously, Dr. Baker was a professor of Chemistry at Harvey Mudd College from 1991-2014 with a research focus on polymer nanostructures and self-assembly. She served on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health, National Science Foundation and the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all of the Synedgen technology.
Kim Snyder, MBA
Chief Financial Officer
Kim has 20 years of experience in financial reporting, budgeting and forecasting, mergers and acquisitions, and divestitures. Her industry experience includes public accounting, manufacturing, pharmaceutical and healthcare in for profit and not for profit organizations. Kim holds a BA in Accounting & Business Management and a MBA with a focus on accounting and finance. As CFO she will manage all contracts, grants, investor funding and financial planning and analysis. Her experience will help drive business improvement initiatives for Synedgen, Prisyna and emerging opportunities.
Christopher Ryan, PhD
Vice President of Pharmaceutical Manufacturing, Secretary
Dr. Christopher Ryan has extensive expertise in polysaccharide structural analysis and interactions of pathogens with human tissue. As VP of Pharmaceutical Manufacturing, Dr. Ryan has been involved in planning and implementing active pharmaceutical ingredient (API) manufacturing and medical device manufacturing. Manufacturing has met the requirements for use of API in non-clinical toxicology studies and clinical trials. He leads the manufacturing team in developing pilot scale batches of new products and provides expertise for scaling manufacturing processes for internal production and for external contract manufacture scale for marketed products. He has overseen contract manufacturing organizations to produce cosmetics, over-the-counter drugs, medical devices, and sterile drug product for clinical trials. He leads quality control personnel in the development of new testing procedures, qualification of equipment, and validation of test methods. He helped establish, and has since overseen, the implementation and continuous improvement of a cGMP quality system. He also helps lead the creation of regulatory affairs documentation to support submissions for medical devices and clinical trials. Dr. Ryan completed a postdoctoral fellowship at the University of California, Los Angeles, where he performed structural analysis of polysaccharide compounds and natural products from T. vaginalis and human pathogens as potential drug targets.
Kaveri Parker, PhD
Chief Business Officer
Dr. Parker leads the commercialization and business development of all Synedgen product divisions, including Wound Care and Prisyna Oral Care, and assists in the expansion of strategic partnership opportunities across the spectrum of Synedgen’s product portfolio. Dr. Parker has an extensive background in biochemistry and infectious diseases, as well as years of business development and management experience. Most recently, she served as President and Chief Executive Officer of ID Genomics Inc. in Seattle, WA, where she led all aspects of executive management, including strategic and tactical planning, fundraising, path-to-market strategy, investor and media relations, as well as R&D capability scale-up. During her tenure, she secured strategic partnerships with 12 major clinical hospital networks across the U.S. and leveraged ID Genomics’ technology into an international microbial surveillance network.
Allister Loughran, PhD
Dr. Loughran is an innovative researcher in the field of infectious disease and neurobiology with a focus on orthopedic and brain infections. As senior scientist, Dr. Loughran provides scientific leadership and oversight and helps drive pharmaceutical product development. Dr. Loughran earned his BSc. in Microbiology and Molecular biology at Monash University, Australia and PhD in Microbiology/Immunology at the University of Arkansas for Medical Sciences before completing a postdoctoral fellowship at St. Jude Children’s Research hospital.
Tim Peters, MS
Director of Program Management
Mr. Peters has 19 years of diverse clinical research management experience in R&D Program Management, Clinical Information Systems/IT, Clinical Data Management and Clinical Trial Operations. His industry experience includes Pharma/Biotech, a Contract Research Organization and a NCI Cooperative Cancer Group. Mr. Peters holds a BS in Biochemistry and MS in Health Evaluation Sciences with an emphasis on Epidemiology and Clinical Trial Methodology. As Director of Program Management, Mr. Peters is responsible for existing and new product oversight, product timelines, and clinical research development.
Jeff Staffa, PhD
Senior FDA Strategist
Dr. Jeffrey A. Staffa has had extensive experience in all aspects of the pharmaceutical industry spanning a career of over 30 years. He has worked for the U.S. FDA, a small privately held company, a small publicly held company, a large publicly held company, and the largest chemical company in the world. He has worked and participated in regulatory affairs, x-ray crystallography, medicinal and agricultural chemical synthesis, pilot plant manufacturing, quality control, safety surveillance, preclinical toxicological evaluation, pharmacokinetics, clinical pharmacology, and clinical development. He has served as the scientific advisor to attorneys working for the federal government and for numerous companies. He has advised Commissioners of the FDA and prepared FDA General Counsel for hearings and trials. He is fluent in the business aspects of the pharmaceutical industry. He has worked with biologics, drugs, devices, foods, and veterinary products.
Merrill Osheroff, PhD
Dr. Osheroff has over 35 years of regulatory expertise in toxicology and drug development, with extensive experience in IND/NDA writing/submissions, program monitoring and management including competitive bidding and negotiations as well as on-site CRO qualifications visits (domestic and overseas), toxicology study monitoring and report review, operational improvements, mentoring and coaching of study directors and other scientific staff, specific topics research and development of white papers, and due diligence activities. Dr. Osheroff has authored multiple Expert Reports/White Papers that have been submitted to the US FDA to support registrations, and is an active member and Treasurer of the Roundtable of Toxicology Consultants.
Philip K. Burns
Quality Assurance Specialist
Mr. Burns has more than 25 years experience in the senior Pharmaceutical Operations environment including site organizational design, management, and product introductions, and Quality Compliance /Technical Production experience including cGMP compliance, Quality Assurance and Compliance, and Regulatory Affairs. He has overseen retooling and reformulation of products produced on the billion-pill scale to building manufacturing facilities for liquids, emulsions and powder/cpasules.
Michael A. Gill
Mr. Gill is a skilled Regulatory, QA, QC compliance specialist with an extensive knowledge of quality assurance and quality control systems, document controls and regulatory requirements. He has 27 years of experience in the pharmaceutical industry with extensive knowledge of managing US FDA, EU and German regulatory authority inspections for US manufacturing facilities, and provides a full service of regulatory and compliance consultation for the pharmaceutical industry, including regulatory, cGMP, cGLP, and cGCP compliance.